论文部分内容阅读
目的:探讨尼莫地平联合益脑脉胶囊治疗高血压性脑出血的疗效。方法:选取2010年1月～2012年5月我院收治的高血压性脑出血患者共78例,随机分为实验组和对照组,每组各39例,其中对照组患者采用甘露醇、胞二磷胆碱与抗氧化剂等常规治疗及尼莫地平静注治疗,1次/天,连续14天,而实验组患者在此基础上加用益脑脉胶囊口服或胃管注入,3次/天,连续28天。分析和比较治疗前及治疗后30天两组患者卒中量表(NIHSS)评分、脑卒中专门生活质量评分表(QLI)评分及临床疗效。结果:治疗后实验组的NIHSS评分明显低于治疗后对照组(P<0.05),治疗后实验组的QLI评分明显高于治疗后对照组,治疗后实验组患者的总有效率明显优于对照组患者(89.74%VS69.23%)。结论:尼莫地平联合益脑脉胶囊治疗高血压性脑出血,可促进病人的神经功能恢复,增加临床疗效,提高生活质量,且安全可靠,值得临床上推广应用。
Objective: To investigate the curative effect of nimodipine combined with yi naomai capsule on hypertensive intracerebral hemorrhage. Methods: From January 2010 to May 2012, 78 patients with hypertensive intracerebral hemorrhage admitted to our hospital were randomly divided into experimental group and control group, with 39 cases in each group. The patients in control group were treated with mannitol, The other two groups were treated with conventional therapy of nalizipine and nimodipine once a day for 14 consecutive days. Patients in the experimental group were given oral or gastric infusion of Yitaimai capsules 3 times a day For 28 consecutive days. The National Institutes of Health Stroke Scale (NIHSS) score, stroke specific quality of life score (QLI) score and clinical efficacy were analyzed and compared before and 30 days after treatment. Results: After treatment, the NIHSS score of the experimental group was significantly lower than that of the control group after treatment (P <0.05). After treatment, the QLI score of the experimental group was significantly higher than that of the control group after treatment. The total effective rate of the experimental group was significantly better than that of the control group Group patients (89.74% VS69.23%). Conclusion: Nimodipine combined with Yitaomai Capsule in the treatment of hypertensive intracerebral hemorrhage can promote the recovery of neurological function, increase the clinical curative effect, improve the quality of life, and is safe and reliable. It is worth popularizing and applying in clinic.